Key result
Lp(a) correlates with LDL-C in hypertensive and diabetic patients but not with coagulation or fibrinolysis.
Observational (n=235)
Lipoprotein(a) levels do not correlate with coagulation or fibrinolysis parameters in hypertensive or diabetic patients, suggesting its cardiovascular risk mechanism may not be directly mediated through these pathways in these populations.
Answers are grounded in this paper and cite their sources.
Lp(a)-LDL correlation without coagulation links in hypertension or diabetes; leaves open alternative risk pathways and needs prospective mechanistic studies.
Lipoprotein(a) (Lp(a)) has been established as an important independent risk factor for the development of cardiovascular disease. Apolipoprotein(a), together with apo B-100 the apolipoprotein of Lp(a), is homologeous to plasminogen but lacks fibrinolytic capacity and appeared to interfere with fibrinolysis in in vitro and ex vivo experiments. We determined the correlations between Lp(a) and other blood lipids (serum cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides), coagulation parameters (fibrinogen, factor VII, factor VIII:C fibrin monomers, thrombin-antithrombin III) and fibrinolysis parameters (tissue plasminogen activator antigen, plasminogen activator inhibitor-1 and D-dimer) in 54 patients with essential hypertension, in 65 non-insulin-dependent diabetic patients and in 116 insulin-regulated diabetic patients. Signs of activated coagulation and increased reactive fibrinolysis were found in all three patient groups. In the hypertensive patients, Lp(a) was significantly correlated with LDL-cholesterol (r = 0.25, P = 0.04) and triglycerides (r = -0.30, P = 0.03), while in insulin-regulated diabetics, Lp(a) was also correlated with LDL-cholesterol (r = 0.20, P = 0.03). In the hypertensive patients and both diabetic groups there was no correlation of Lp(a) with coagulation or fibrinolysis parameters. These data show that Lp(a) concentrations are not related to coagulation or fibrinolysis parameters in hypertensive or diabetic patients and confirm the presence of an activated coagulation system in these patient groups.
No takes yet. Share an insight, caveat, or question.
Donders et al. (1992) conducted an observational in Essential hypertension and diabetes mellitus (n=235). Lipoprotein(a) was evaluated on Correlation of Lp(a) with blood lipids, coagulation, and fibrinolysis parameters. Lipoprotein(a) correlated with LDL-cholesterol in hypertensive and insulin-regulated diabetic patients, but not with coagulation or fibrinolysis parameters.
Synapse has enriched 10 related papers. Consider them for comparative context: